GEP20001940B - Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment - Google Patents

Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment

Info

Publication number
GEP20001940B
GEP20001940B GEAP19963845A GEAP1996003845A GEP20001940B GE P20001940 B GEP20001940 B GE P20001940B GE AP19963845 A GEAP19963845 A GE AP19963845A GE AP1996003845 A GEAP1996003845 A GE AP1996003845A GE P20001940 B GEP20001940 B GE P20001940B
Authority
GE
Georgia
Prior art keywords
treatment
processes
producing
crystalline form
anhydrous crystalline
Prior art date
Application number
GEAP19963845A
Other languages
English (en)
Inventor
James Wotrap David
David Michael Skinner
Philip George Lake
Gregory Alan Conway
William Bayne Grubb Iii
Richard Augustus Winnike
Peter Gregory Varlashkin
Jane Muse Partin
Barry Howard Carter
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20001940(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of GEP20001940B publication Critical patent/GEP20001940B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GEAP19963845A 1995-01-20 1996-01-19 Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment GEP20001940B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (1)

Publication Number Publication Date
GEP20001940B true GEP20001940B (en) 2000-02-05

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP19963845A GEP20001940B (en) 1995-01-20 1996-01-19 Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment

Country Status (40)

Country Link
US (1) US6107302A (enExample)
EP (1) EP0804436B1 (enExample)
JP (1) JP3176633B2 (enExample)
KR (1) KR100376074B1 (enExample)
CN (1) CN1049893C (enExample)
AP (1) AP662A (enExample)
AR (1) AR002270A1 (enExample)
AT (1) ATE302777T1 (enExample)
AU (1) AU702794B2 (enExample)
BG (1) BG63393B1 (enExample)
BR (1) BR9606768A (enExample)
CA (1) CA2210799C (enExample)
CY (1) CY2531B1 (enExample)
CZ (1) CZ297065B6 (enExample)
DE (1) DE69635106T2 (enExample)
DK (1) DK0804436T3 (enExample)
EA (1) EA000364B1 (enExample)
EE (1) EE03528B1 (enExample)
ES (1) ES2248806T3 (enExample)
FI (1) FI973063A7 (enExample)
GB (1) GB9501178D0 (enExample)
GE (1) GEP20001940B (enExample)
HR (1) HRP960024B1 (enExample)
HU (1) HU222993B1 (enExample)
IL (1) IL116831A (enExample)
IN (1) IN182468B (enExample)
IS (1) IS2268B (enExample)
NO (1) NO315558B1 (enExample)
NZ (1) NZ298851A (enExample)
OA (1) OA10499A (enExample)
PL (1) PL182175B1 (enExample)
RO (1) RO118693B1 (enExample)
RS (1) RS49518B (enExample)
SI (1) SI0804436T1 (enExample)
SK (1) SK285329B6 (enExample)
TR (1) TR199700656T1 (enExample)
UA (1) UA46001C2 (enExample)
UY (1) UY25779A1 (enExample)
WO (1) WO1996022291A1 (enExample)
ZA (1) ZA96449B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
DK0874631T3 (da) * 1996-01-19 2004-03-22 Glaxo Group Ltd Anvendelse af valaciclovir til fremstilling af et medikament til behandling af genital herpes ved en enkelt daglig anvendelse
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
WO1998031683A1 (en) * 1997-01-17 1998-07-23 Ajinomoto Co., Inc. Novel z-valacyclovir crystals
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
HRPK20110926B3 (hr) * 2001-02-24 2013-05-31 Boehringer Ingelheim Pharma Gmbh & Co.Kg. Derivati ksantina, njihova proizvodnja i upotreba kao lijekova
US6849736B2 (en) * 2001-09-07 2005-02-01 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
US20040197396A1 (en) * 2001-11-05 2004-10-07 Fain Helen S Anhydrous crystal form of valaciclovir hydrochloride
KR20050044449A (ko) * 2001-11-14 2005-05-12 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르의 합성 및 정제 방법
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
US20050085491A1 (en) * 2003-06-02 2005-04-21 Igor Lifshitz Novel crystalline forms of valacyclovir hydrochloride
TW200536854A (en) * 2004-01-21 2005-11-16 Teva Pharma Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
JP2008504255A (ja) * 2004-06-30 2008-02-14 テバ ファーマシューティカル インダストリーズ リミティド 結晶塩酸バラシクロビル中の残留アルコールを低減する方法
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
EP1891071B1 (en) * 2005-05-25 2012-02-22 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
MX2008014024A (es) * 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
EP2190434B1 (en) * 2007-08-17 2019-04-17 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
WO2009031576A1 (ja) * 2007-09-03 2009-03-12 Ajinomoto Co., Inc. バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101657960B1 (ko) * 2008-08-15 2016-09-20 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ-관련 질환의 치료에 사용하기 위한 푸린 유도체
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
PH12012502162A1 (en) 2010-05-05 2013-02-04 Boehringer Ingelheim Int Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
KR102018038B1 (ko) 2010-06-24 2019-09-05 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
EP2852592A4 (en) * 2011-11-25 2015-12-23 Piramal Entpr Ltd PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
EP0702682B1 (en) * 1993-06-10 2001-03-14 Rolabo Sl Process for the preparation of amino acid esters of nucleoside analogues
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
GB9501178D0 (en) 1995-03-08
HRP960024B1 (en) 2005-08-31
IS2268B (is) 2007-07-15
JP3176633B2 (ja) 2001-06-18
RS49518B (sr) 2006-10-27
IL116831A (en) 1998-10-30
ZA96449B (en) 1996-08-07
AU4453996A (en) 1996-08-07
DE69635106D1 (de) 2005-09-29
KR19980701525A (ko) 1998-05-15
FI973063A0 (fi) 1997-07-18
DE69635106T2 (de) 2006-06-08
HU222993B1 (hu) 2004-01-28
BG101833A (bg) 1998-04-30
NO973326L (no) 1997-09-16
SK96597A3 (en) 1998-02-04
IS4527A (is) 1997-07-15
HUP9801836A3 (en) 1999-06-28
AP9701058A0 (en) 1997-10-31
IN182468B (enExample) 1999-04-17
DK0804436T3 (da) 2005-12-27
EE9700175A (et) 1998-02-16
HRP960024A2 (en) 1997-10-31
KR100376074B1 (ko) 2003-06-02
AR002270A1 (es) 1998-03-11
PL182175B1 (pl) 2001-11-30
FI973063L (fi) 1997-09-18
FI973063A7 (fi) 1997-09-18
CN1179159A (zh) 1998-04-15
YU3396A (sh) 1998-12-23
NO973326D0 (no) 1997-07-18
EA199700124A1 (ru) 1997-12-30
AU702794B2 (en) 1999-03-04
US6107302A (en) 2000-08-22
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
AP662A (en) 1998-08-19
MX9705462A (es) 1997-10-31
ES2248806T3 (es) 2006-03-16
TR199700656T1 (xx) 1998-03-21
IL116831A0 (en) 1996-05-14
CA2210799C (en) 2008-06-10
CA2210799A1 (en) 1996-07-25
SK285329B6 (sk) 2006-11-03
UY25779A1 (es) 2000-08-21
EP0804436B1 (en) 2005-08-24
PL321326A1 (en) 1997-12-08
ATE302777T1 (de) 2005-09-15
BR9606768A (pt) 1997-12-30
SI0804436T1 (sl) 2006-02-28
EP0804436A1 (en) 1997-11-05
JPH11503718A (ja) 1999-03-30
RO118693B1 (ro) 2003-09-30
NZ298851A (en) 1999-01-28
EA000364B1 (ru) 1999-06-24
CZ297065B6 (cs) 2006-08-16
UA46001C2 (uk) 2002-05-15
OA10499A (en) 2002-04-10
EE03528B1 (et) 2001-10-15
NO315558B1 (no) 2003-09-22
CZ229497A3 (en) 1997-12-17
CY2531B1 (en) 2006-04-12
WO1996022291A1 (en) 1996-07-25
HUP9801836A2 (hu) 1999-05-28

Similar Documents

Publication Publication Date Title
GEP20001940B (en) Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment
CA2213339A1 (en) Method of treating adenosine depletion
HU913396D0 (en) Process for the production of azasteroide compounds and medical preparations containing them as active agents
MY114132A (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases.
DE69329887D1 (de) Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
HU9600957D0 (en) Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
RU94041950A (ru) Использование соединений ряда 3-аролоксипропиламинов в лечении недержания
MX9707197A (es) Compuestos triciclicos de urea que son utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proliferativas.
HU9201258D0 (en) Process for the production of medical preparations for treating hiv infections and of their active agents
TNSN87015A1 (fr) Nouvelles n-heterocyclyl-4-piperidinamines, compositions contenant des n-heterocyclyl-4-piperidinamines, procede de traitement les utilisant et procede pour preparer des n-heterocyclyl-4- piperidinamines
PH30250A (en) Substituted cyclohexane derivatives processes for their preparation and the use of the compounds for treating diseases
HU903961D0 (en) Process for producing 11-beta-aryl-4-oestrenes and pharmaceutical preparatives containing these compounds
ES8304969A1 (es) Procedimiento para la obtencion de 2-aril-3,4-diazabiciclo 4.n.0-alq-2-en-5-onas.
ES8607916A1 (es) Un procedimiento para la preparacion de medicamentos influenciadores de la circulacion sanguinea, que contienen compuestos de bis (carboxamida)
IL85932A (en) 1-pyridyl (or pyrimidyl)-4-diphenylbutyl piperazines, process for their preparation and pharmaceutical compositions containing them
HUT61199A (en) Process for producing pharmaceutical compositions suitable for treating hyperlipidaemia and/or atherosclerosis
JPS6452726A (en) Method for removing endotoxin of pertussis, pertussis toxoid and production thereof
FR2651769B1 (fr) Procede de traitement, par fermentation anaerobie, d'eaux residuaires en vue de l'elimination de la matiere organique et des sulfates qu'elles contiennent.
DE69103087D1 (de) N-substituierte Trifluormethylphenyltetrahydropyridine, Verfahren zur Herstellung, Zwischenprodukte, sowie Arzneimittel, die solche enthalten.
MD1687F2 (en) Arylthiocompounds, pharmaceutical composition, methods of bacterial and viral infections treatment
HUT45250A (en) Process for producing 5-substituted octahydro-indolysin derivatives and pharmaceutical compositions containing them as active components
FR2682950B1 (fr) Procede d'elimination de la diethanolamine presente dans la triethanolamine et procede de preparation de triethanolamine purifiee.
GR900100332A (en) Process for preparation of phenoxypropanolamines pharmaceutical compositions containing them and their use as antiobesity agents
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
GR1002251B (en) Process for preparing clystalline (5r,6s)-2-carbamouloxymethyl-6-£(1r)-hydroxyethyl|-2-penem-carboxylic acid and its pharmaceutical formulation